The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.

Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.

Restructuring Updates: Homology implemented modest job cuts as it ended a gene therapy trial, while ProQR revealed its second round of layoffs this year and Synthetic Biologics shifted focus to oncolytic virus pipeline. Also, Bolt, MacroGenics and others deprioritized programs in their Q2 updates.

The major will use funds from the sale of its male hypogonadism product to invest in future innovation, which is likely to focus on high-risk high-reward cell and gene drug candidates.